ClinicalTrials.gg
RecruitingNCT07486830Updated Mar 23, 2026

IncobotulinumtoxinA for Provoked Vestibulodynia With Overactive Pelvic Floor Muscle Dysfunction

A Phase 2 interventional study of Incobotulinum Toxin A and Placebo in Provoked Vestibulodynia, sponsored by Center for Vulvovaginal Disorders. Recruiting at 2 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by Center for Vulvovaginal Disorders · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Vulvodynia with a site in United States — 8 open to participants now, 9 under way, 1 of them phase 3. Vulvodynia · United States.

Planned enrollment
13th of 36
54 · median 45
Started
2026
with 2 others
Phase 2
10 of 47
3 open now
Registered
46th of 47
by date
Lead sponsor
2 of 47
Center for Vulvovaginal Disorders

Among the 47 studies in Vulvodynia with a site in United States, this one is the 13th largest by planned enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2026, is one of 10 in phase 2, and was the 46th registered.

Vulvodynia

117 studies on the registry are indexed under Vulvodynia; 21 are open to participants now.

Browse Vulvodynia studies →

Open to participants now

8 of the 47 studies in Vulvodynia with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Vulvodynia studies recruiting now, 8 (62%) set no upper age limit and 5 (38%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Vulvodynia with a site in United States, or all of them as a file.
02

Study summary

This is a double-blind, placebo-controlled study evaluating the safety and efficacy of incobotulinumtoxinA (Merz) for the treatment of provoked vestibulodynia (PVD) associated with overactive pelvic floor muscle dysfunction. Eligible participants are premenopausal females aged 18 years and older with a confirmed diagnosis of PVD with hypertonic pelvic floor muscles, established by both an expert physician and an expert pelvic floor physical therapist. Participants must have bilateral provoked pain at the posterior vestibule on cotton swab testing and a pain score of 5 or greater on an 11-point Numeric Rating Scale (NRS) during standardized dilator testing at baseline. Key outcome measures include change in pain during dilator testing and Patient Global Impression of Change (PGI-C). Participants with anterior vestibular pain, prior botulinum toxin injection in the genitopelvic area within the past 12 months, or significant genitourinary conditions that may confound assessment are excluded.

03

Conditions studied

  • Provoked Vestibulodynia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female, 18 years or older.

    • Willing to provide a written prior to any study related procedures.
    • Premenopausal.
    • Have vulvodynia with provoked vestibulodynia with overactive pelvic floor muscle dysfunction for at least 3 months duration and for no more than 15 years.
    • Have provoked pain at the posterior vestibule on a cotton swab test, with pain at positions 4, 6 and 8 o'clock (must be bilateral pain) at the Baseline Visit.
    • Have independently confirmed diagnoses of provoked vestibulodynia PVD with overactive pelvic floor muscle dysfunction (hypertonic pelvic floor muscles) confirmed by both an expert physician and expert pelvic floor physical therapist.
    • Are able to tolerate the smallest dilator size (diameter 0.5 inches) at the Baseline Visit, i.e. agree to the next successive dilator size to be tested for pain response (i.e. the two smallest sized dilators (#1 and 2) are to be tested).
    • Pain score ≥5 on an 11-point Numeric Rating Scale (NRS) for the Dilator Maximum Tested Size (DMTS) at the Baseline Visit.
    • Willing and able to comply with study restrictions, able to attend the clinic for the required duration of assessments during the study period and willing to return to the clinic for the follow-up evaluation as specified in the protocol.
    • If the subject has received oral antidepressants, anxiolytics or anti-epileptics, then the dose of these medications should have been stable for at least 3 months prior to the Baseline Visit and expected to remain stable throughout the study.
    • If the subject is currently undergoing pelvic floor physical therapy then the frequency of visits should be stable for at least 8 weeks prior to the Baseline visit and expected to remain stable throughout the study.
    • If the subject has vaginal/vulvar infections (bacterial vaginosis, presence of candidiasis or trichomoniasis) at Baseline Visit (provider will take a vaginal culture swab to test for infection), they may still participate as long as they undergo treatment for the infection (as prescribed by study provider).

Exclusion criteria

Exclusion Criteria:

  • Have provoked pain on a cotton swab test at the anterior vestibule (anywhere between 9 and 3 o'clock or more anteriorly) at the Baseline Visit.

    • Able to tolerate the 6th (diameter 1 1⁄4 inches) dilator size (i.e. agree to the next successive dilator size to be tested for pain response) at the Baseline Visit with a pain score less than 5 (i.e. blue dilator).
    • Genitourinary or gastrointestinal conditions/history which, according to the investigator's judgment may interfere with treatment or impact outcome assessment, including but not limited to:
    • Skin disease at the vestibule such as lichen sclerosus, lichen planus, vaginal or vulvar atrophy, desquamative inflammatory vaginitis, allergic vulvitis, etc.
    • Severe endometriosis (as defined as requiring regular medications other than hormonal and NSAIDS to manage the endometriosis symptoms).
    • Pudendal neuralgia (as defined as greater than minimal tenderness to palpation of the pudendal nerves at the ischial spine).
    • Genitourinary or rectal cancer.
    • Congenital urogenital abnormalities (e.g. vaginal septa, imperforate hymen, urethral diverticulum).
    • Pain in urethra (diagnosis based on subject's interview and physical examination).
    • Symptomatic urogenital prolapse at physical examination.
    • History of traumatic or post radiotherapy vulvar lesions.
    • Previous surgery that according to the investigator's judgment may impact on study outcome including but not limited to vaginal hysterectomy, vestibulectomy, urolxogic surgery (slings, colporrhaphy, etc.), perianal surgery or genital trauma or mutilation/cutting.
    • Current vaginal/vulvar infections (bacterial vaginosis, candidiasis, or trichomoniasis) and are unwilling or unable to take oral medication to treat this infection.
    • history of alcohol/drug abuse the last 24 weeks prior to Baseline or clinically significant alcohol/drug dependence within 2 years prior to Baseline. Exceptions include caffeine or nicotine abuse/dependence.
    • Has received any of the following:
    • Pelvic floor physical therapy initiated, stopped or modified (frequency or type of physical therapy) during the last 8 weeks prior to Baseline (physical therapy includes but is not limited to: internal/external myofascial release by physical therapist, biofeedback, home pelvic floor exercises, self-taught exercises, use of vaginal dilators, etc.).
    • Treatment with any muscle relaxants in the past 2 weeks.
    • Treatment for anterior vestibular pain, with hormonal creams, in the last 1 week prior to Baseline unless continued at the same dosing regimen throughout the study.
    • Currently receiving treatment for stress or urge urinary incontinence.
    • Injections of in the vulva within the last 4 weeks prior to the Baseline Visit or planned use during the study.
    • Injection of BoNT in the genitopelvic area within the last 12 months prior to the Baseline visit.
    • Treatment with an drug within the last 4 weeks prior to Baseline or scheduled treatment with such a drug during the study period.
    • Is likely to require treatment during the study with drugs that are not permitted by the study protocol.
    • Any mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study, and/or evidence of an uncooperative attitude, as judged by the investigator.
    • Women who are pregnant or planning to become pregnant during the study, or who are currently lactating (breastfeeding). Participants should either not have sexual intercourse with a male partner or should use a method of birth control that is acceptable to them and the study doctor during the time that they participate in the protocol. Acceptable forms of contraceptives include: progestin and/or estrogen-containing hormonal contraceptives, contraceptive patch, contraceptive implant, contraceptive injection, condoms, or progestin or copper-containing intrauterine device (IUD), tubal sterilization, vasectomy of all sexual partners.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    INA group

    Drug: Incobotulinum Toxin A

  • Placebo comparator
    Placebo Group

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Dilator Maximum Tested Size

    maximum dilator size tolerated

    Time frame: baseline, week 24-30 (final visit)

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2026
First posted
Mar 23, 2026
StartActual
Feb 27, 2026
Primary completionEst.
Dec 20, 2026
CompletionEst.
Mar 3, 2027
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07486830
Lead sponsor
Center for Vulvovaginal Disorders
Collaborators
Merz Pharmaceuticals
Responsible party
Sponsor
First posted
Mar 23, 2026
Start date
Feb 27, 2026
Primary completion
Dec 20, 2026 (estimated)
Completion
Mar 3, 2027 (estimated)
Last update
Mar 23, 2026

Study contacts

Andrew Goldstein, MD
Contact
obstetrics@yahoo.com
202-887-0568

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion